Drugs / CT1-DAP001
CT1-DAP001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06482268 | Jun 2024 → Feb 2025 overdue | Parkinson disease | University of California, San Diego | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-12-26 | Sumitomo Pharma America, Inc. | Regulatory Start of Investigator-Initiated Clinical Study of iPS Cell-Derived Dopaminergic Progenitor Cells for Parkinson’s Disease in the United States sumitomo-pharma.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-12-26 | Sumitomo Pharma America, Inc. | Start of Investigator-Initiated Clinical Study of iPS Cell-Derived Dopaminergic Progenitor Cells for Parkinson’s Disease in the United States sumitomo-pharma.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT1-DAP001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06482268 ↗ |
| Known as | Human induced pluripotent stem cell-derived dopaminergic progenitors | “Human induced pluripotent stem cell-derived dopaminergic progenitors (CT1-DAP001)” NCT06482268 ↗ |
| Modality | Cell therapy | “human induced pluripotent stem cell-derived dopaminergic progenitors” NCT06482268 ↗ |
| Route | Other | “into the corpus striatum” NCT06482268 ↗ |